Last reviewed · How we verify
NCT07272655
AAR/AAR+HAR vs AAR+TAR+FET for Type A Aortic Intramural Hematoma
NA trial testing Ascending Aorta Replacement / Ascending Aorta Plus Hemiarch Replacement in Aortic Intramural Hematoma in 400 participants. Not yet recruiting.
30 April 2027
Quick facts
| Lead sponsor | Second Hospital of Jilin University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 1 April 2026 |
| Primary completion | 30 April 2027 |
| Estimated completion | 30 October 2027 |
Drugs / interventions tested
- Ascending Aorta Replacement / Ascending Aorta Plus Hemiarch Replacement
- Ascending Aorta Replacement With Total Arch Replacement and Frozen Elephant Trunk
Conditions studied
- Aortic Intramural Hematoma — all drugs for Aortic Intramural Hematoma →
Sponsor
Second Hospital of Jilin University
Who can join
Adults 18 to 80, any sex, with Aortic Intramural Hematoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, randomized, non-inferiority clinical trial designed to compare the efficacy and safety of two surgical strategies for acute type A aortic intramural hematoma (TAIMH): (1) ascending aorta replacement or ascending aorta plus hemiarch replacement (AAR/AAR+HAR), and (2) ascending aorta replacement with total arch replacement and frozen elephant trunk implantation (AAR+TAR+FET). Patients will be enrolled based on CTA confirmation of a completely thrombosed false lumen in the ascending aorta and aortic arch. Eligible participants will be randomized in a 1:1 ratio to either group. The primary endpoint is the rate of reintervention on the aortic arch or descending aorta from 6 to 12 months after surgery. Secondary endpoints include circulatory arrest time, aortic cross-clamp time, operation time, major adverse cardiovascular events, other perioperative complications, and total hospitalization cost. A total of 400 participants will be enrolled.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07272655
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Second Hospital of Jilin University trials
Trials by the same sponsor.
- NCT07057713 — Total Arterial vs. Mixed Grafting in Left Coronary CABG · NA · not yet recruiting
- NCT06787651 — Comparison of RIMA-SVG and Ao-SVG Techniques in Coronary Artery Bypass Grafting · NA · active not recruiting
- NCT06218160 — The Addition of Hydromorphone to Local Anesthetics for the Repair of Inguinal Hernias in Elderly Patients · NA · completed
- NCT06205199 — Analgesic Effect of Ropivacaine Combined With Hydromorphone for CSEA After Total Knee Arthroplasty · NA · completed
- NCT06240858 — Clinical Study of Self-gripping Mesh in TAPP Versus Lichtenstein Hernia Repair · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07272655 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Hospital of Jilin University
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07272655.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing